Statin therapy for young adults: A long-term investment worth considering

HMG coenzyme A reductase inhibitors (statins) significantly decrease low-density lipoprotein-cholesterol, resulting in stabilization, and in some cases regression, of atherosclerotic plaque with subsequent reduction in atherosclerotic cardiovascular disease (ASCVD) events. To date, there remains a p...

Full description

Saved in:
Bibliographic Details
Published in:Trends in cardiovascular medicine 2020-01, Vol.30 (1), p.48-53
Main Authors: Miedema, Michael D., Nauffal, Victor D., Singh, Avinainder, Blankstein, Ron
Format: Article
Language:English
Subjects:
Arteriosclerosis
Atherosclerosis
Atherosclerotic cardiovascular disease
Calcification (ectopic)
Calcium
Cardiovascular disease
Cardiovascular diseases
Cholesterol
Coenzyme A
Coronary artery
Decision making
Health risk assessment
Hypercholesterolemia
Inflammatory diseases
Lipoprotein
Low density lipoprotein
Mortality
Reductase
Risk assessment
Risk factors
Statins
Young adults
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:HMG coenzyme A reductase inhibitors (statins) significantly decrease low-density lipoprotein-cholesterol, resulting in stabilization, and in some cases regression, of atherosclerotic plaque with subsequent reduction in atherosclerotic cardiovascular disease (ASCVD) events. To date, there remains a paucity of data to guide the use of statins in young adults (20–49 years old). We herein aim to summarize the potential benefits and risks for statin therapy in younger adults, outlining a possible approach to statin use in young adults. Early identification and treatment of young individuals at risk for ASCVD offers the potential to significantly reduce the lifetime risk of ASCVD. However, there is a paucity of data on the potential side effects of long-term statin use over many decades. Comprehensive risk assessment, including calculation of life-time ASCVD risk, as well as incorporating non-traditional risk factors including lipoprotein (a), strong family history of premature ASCVD, familial hypercholesterolemia, LDL-C level and presence of underlying systemic inflammatory disorders can be helpful in identifying young adults who stand to benefit the most from statin therapy. Selective use of coronary artery calcium (CAC) assessment, as well as potentially polygenic risk scores, can be considered in situations where there remains uncertainty regarding risk assessment. Importantly, the decision for statin treatment should occur in the context of a patient centered shared decision-making process.
ISSN:1050-1738
1873-2615
DOI:10.1016/j.tcm.2019.02.004